• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

Latest: Watch here for details of new products and services.

Pharmalicensing
is a division of
UTEK Europe Ltd

— PARIS, October 1

PARIS, October 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, Japan has selected the CATANIA(TM) Coronary Stent System featuring NanoThin Polyzene(R)-F for treating a patient with a chronic total occlusion (CTO) during a live case symposium at the Paris Cardiovascular Interventions (Francophone) Congress. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080-a ) (Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )

Chronic total occlusion is defined as any artery where blood flow has been completely blocked for greater than 30 days. These types of lesions are exceptionally difficult to treat with percutaneous intervention (angioplasty) because of the challenges physicians face in crossing the lesion to move the catheter into place for proper stent deployment. The CATANIA(TM) Stent was selected for this live case because Polyzene(R)-F makes it highly lubricious and delivers low restenosis rates, excellent anti-thrombosis rates, and other clinical benefits that approach or, in some cases, may exceed those of DES, while addressing some of the significant ongoing concerns with current DES technology such as product cost, risk for thrombosis, and serious challenges associated with costly long-term dual anti-platelet therapy following treatment.

"The CATANIA(TM) Stent has superb pushability, trackability, and flexibility. You can feel that the Polyzene(R)-F surface is slicker than other stents," said Thierry Corcos, MD, Service de Cardiologie, Clinique Turin, Paris, France. "For the live case, we want to really test the CATANIA(TM) Stent's capabilities in a challenging anatomy, because of the clinical evidence that Polyzene(R)-F nanocoating prevents thrombosis, restenosis and reocclusion. Based on my experience, I believe the CATANIA(TM) Stent is an ideal choice for treating coronary artery disease, including chronic total occlusions."

The rapid-exchange, cobalt-chromium CATANIA(TM) Stent features a modified open-cell design and is available in 60 sizes in lengths from 8mm to 38mm and in diameters, from 2.0 to 4.0mm. The CATANIA(TM) Stent does not contain any drugs, off-loaded materials or biological substitutes. The proprietary nanothin, highly lubricious Polyzene(R)-F is a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation. This unique combination of stent and surface treatment effectively creates a new and different class of stent that does not require long-term dual anti-platelet therapy.

"It is exceptionally gratifying that Dr. Corcos and Dr. Ochiai selected to showcase the abilities of the CATANIA(TM) Stent in such an important, and difficult-to-treat live case, because we design all of our products from the ground up using direct feedback from the physicians who use them," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "We are looking forward to presenting the CATANIA(TM) long-term, First-In-Man data on the world stage later this month during the Transcatheter Therapeutics (TCT) annual meeting in Washington, DC."

For more information about CeloNova BioSciences' products and Polyzene(R)-F technology, visit www.celonova.com .

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit www.celonova.com .

CONTACT: Robert J. Murphy The Storch-Murphy Group +1-908-276-0777

Web site: http://www.celonova.com

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us